Playback speed
10 seconds
Updates on HR+ and HER2+ Advanced Breast Cancer
By
OncoAlert
FEATURING
Erika Hamilton
By
OncoAlert
FEATURING
Erika Hamilton
603 views
February 15, 2023
This video was recorded prior to FDA approval of ORSERDU™ (elacestrant) on January 27, 2023 ...
read more ↘ in ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed on at least 1 line of endocrine therapy
↖ read less
read more ↘ in ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed on at least 1 line of endocrine therapy
↖ read less
Login to view comments.
Click here to Login